A Pan-Pneumovirus Vaccine Based on Immunodominant Epitopes of the Fusion Protein

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Aug 25

PMID 36003370

Authors

Jiachen Huang

Rose J Miller

Jarrod J Mousa

Affiliations

Soon will be listed here.

Abstract

Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are two leading causes of severe respiratory infections in children, the elderly, and immunocompromised patients. The fusion (F) protein is the major target of neutralizing antibodies. Recent developments in stabilizing the pre-fusion conformation of the F proteins, and identifying immunodominant epitopes that elicit potent neutralizing antibodies have led to the testing of numerous pre-fusion RSV F-based vaccines in clinical trials. We designed and tested the immunogenicity and protective efficacy of a chimeric fusion protein that contains immunodominant epitopes of RSV F and hMPV F (RHMS-1). RHMS-1 has several advantages over vaccination with pre-fusion RSV F or hMPV F, including a focus on recalling B cells to the most important protective epitopes and the ability to induce protection against two viruses with a single antigen. RHMS-1 was generated as a trimeric recombinant protein, and analysis by negative-stain electron microscopy demonstrated the protein resembles the pre-fusion conformation. Probing of RHMS-1 antigenicity using a panel of RSV and hMPV F-specific monoclonal antibodies (mAbs) revealed the protein retains features of both viruses, including the pre-fusion site Ø epitope of RSV F. Mice immunized with RHMS-1 generated neutralizing antibodies to both viruses and were completely protected from RSV or hMPV challenge. Overall, this study demonstrates protection against two viruses with a single antigen and supports testing of RHMS-1 in additional pre-clinical animal models.

Citing Articles

Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus.

Lee Y, Han J, Zhang Y, Ward G, Gomes K, Auclair S Nat Commun. 2024; 15(1):9939.

PMID: 39550381 PMC: 11569192. DOI: 10.1038/s41467-024-54287-x.

Human monoclonal antibodies protect against viral-mediated pneumococcal superinfection.

Gingerich A, Mahoney L, McCormick A, Miller R, Mousa J Front Immunol. 2024; 15:1364622.

PMID: 38933273 PMC: 11199387. DOI: 10.3389/fimmu.2024.1364622.

A tale of two fusion proteins: understanding the metastability of human respiratory syncytial virus and metapneumovirus and implications for rational design of uncleaved prefusion-closed trimers.

Lee Y, Han J, Zhang Y, Ward G, Gomes K, Auclair S bioRxiv. 2024; .

PMID: 38496645 PMC: 10942449. DOI: 10.1101/2024.03.07.583986.

Structural basis for respiratory syncytial virus and human metapneumovirus neutralization.

Miller R, Mousa J Curr Opin Virol. 2023; 61:101337.

PMID: 37544710 PMC: 10421620. DOI: 10.1016/j.coviro.2023.101337.

References

Gilman M, Furmanova-Hollenstein P, Pascual G, van t Wout A, Langedijk J, McLellan J . Transient opening of trimeric prefusion RSV F proteins. Nat Commun. 2019; 10(1):2105. PMC: 6506550. DOI: 10.1038/s41467-019-09807-5. View

Bao X, Kolli D, Liu T, Shan Y, Garofalo R, Casola A . Human metapneumovirus small hydrophobic protein inhibits NF-kappaB transcriptional activity. J Virol. 2008; 82(16):8224-9. PMC: 2519579. DOI: 10.1128/JVI.02584-07. View

Buchholz U, Biacchesi S, Pham Q, Tran K, Yang L, Luongo C . Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity. J Virol. 2005; 79(11):6588-97. PMC: 1112115. DOI: 10.1128/JVI.79.11.6588-6597.2005. View

Dowell S, Anderson L, Gary Jr H, Erdman D, Plouffe J, File Jr T . Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis. 1996; 174(3):456-62. DOI: 10.1093/infdis/174.3.456. View

Wilson R, Fuentes S, Wang P, Taddeo E, Klatt A, Henderson A . Function of small hydrophobic proteins of paramyxovirus. J Virol. 2006; 80(4):1700-9. PMC: 1367141. DOI: 10.1128/JVI.80.4.1700-1709.2006. View

CHANOCK R, FINBERG L . Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. Am J Hyg. 1957; 66(3):291-300. DOI: 10.1093/oxfordjournals.aje.a119902. View

Nachbagauer R, Feser J, Naficy A, Bernstein D, Guptill J, Walter E . A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med. 2020; 27(1):106-114. DOI: 10.1038/s41591-020-1118-7. View

Lo M, Brazas R, Holtzman M . Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol. 2005; 79(14):9315-9. PMC: 1168759. DOI: 10.1128/JVI.79.14.9315-9319.2005. View

Zhang W, Yang H, Kong X, Mohapatra S, Juan-Vergara H, Hellermann G . Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med. 2004; 11(1):56-62. DOI: 10.1038/nm1174. View

10.

Ruckwardt T, Morabito K, Phung E, Crank M, Costner P, Holman L . Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. Lancet Respir Med. 2021; 9(10):1111-1120. PMC: 8487912. DOI: 10.1016/S2213-2600(21)00098-9. View

11.

Stewart-Jones G, Gorman J, Ou L, Zhang B, Joyce M, Yang L . Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses. Proc Natl Acad Sci U S A. 2021; 118(39). PMC: 8488613. DOI: 10.1073/pnas.2106196118. View

12.

Battles M, Mas V, Olmedillas E, Cano O, Vazquez M, Rodriguez L . Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein. Nat Commun. 2017; 8(1):1528. PMC: 5688127. DOI: 10.1038/s41467-017-01708-9. View

13.

Correia B, Bates J, Loomis R, Baneyx G, Carrico C, Jardine J . Proof of principle for epitope-focused vaccine design. Nature. 2014; 507(7491):201-6. PMC: 4260937. DOI: 10.1038/nature12966. View

14.

Panda S, Mohakud N, Pena L, Kumar S . Human metapneumovirus: review of an important respiratory pathogen. Int J Infect Dis. 2014; 25:45-52. PMC: 7110553. DOI: 10.1016/j.ijid.2014.03.1394. View

15.

Wu H, Pfarr D, Johnson S, Brewah Y, Woods R, Patel N . Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007; 368(3):652-65. DOI: 10.1016/j.jmb.2007.02.024. View

16.

Nachbagauer R, Kinzler D, Choi A, Hirsh A, Beaulieu E, Lecrenier N . A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice. NPJ Vaccines. 2017; 1. PMC: 5707880. DOI: 10.1038/npjvaccines.2016.15. View

17.

Mas V, Rodriguez L, Olmedillas E, Cano O, Palomo C, Terron M . Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation. PLoS Pathog. 2016; 12(9):e1005859. PMC: 5017722. DOI: 10.1371/journal.ppat.1005859. View

18.

Olmedillas E, Cano O, Martinez I, Luque D, Terron M, McLellan J . Chimeric fusion proteins as immunogens to induce cross-neutralizing antibody responses. EMBO Mol Med. 2017; 10(2):175-187. PMC: 5801496. DOI: 10.15252/emmm.201708078. View

19.

Shirogane Y, Takeda M, Iwasaki M, Ishiguro N, Takeuchi H, Nakatsu Y . Efficient multiplication of human metapneumovirus in Vero cells expressing the transmembrane serine protease TMPRSS2. J Virol. 2008; 82(17):8942-6. PMC: 2519639. DOI: 10.1128/JVI.00676-08. View

20.

Stokes A, Franklin K, Fisher D, Posobiec L, Binazon O, Tripathi N . Repeated Dose Toxicity Study and Developmental and Reproductive Toxicology Studies of a Respiratory Syncytial Virus Candidate Vaccine in Rabbits and Rats. Int J Toxicol. 2021; 40(2):125-142. DOI: 10.1177/1091581820985782. View